TZTianyun Zhao

Tianyun Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tianyun Zhao has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Ziwen Shi

    Department of Anesthesiology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University,Guangzhou, China

    3 shared publications
  • Junming Lu

    Department of Anesthesiology, Guangdong Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine), 510120 Guangzhou, Guangdong, China

    2 shared publications
  • Xingrong Song

    Department of Anesthesiology, Guangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou China

    2 shared publications
  • Chuanxiang Li

    Department of Anesthesiology, Third Affiliated Hospital of Southern Medical University, Guangzhou, China

    1 shared publication
  • Chuanxiang Li

    School of Missile Engineering, Rocket Force University of Engineering, Xian, China

    1 shared publication
  • Daqing Ma

    Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea & Westminster Hospital, London, UK

    1 shared publication

Latest Publications

  • Open Access

    Therapeutic Values of General Anesthetics: From Developmental Neurotoxicity to Neurotherapeutic Agents

    by Tianyun Zhao, Xinying Guo, Ziwen Shi, Haiping Xu, Shiqi Deng, Hangchao Tang, Hui Cai, Xingrong Song

    The development of the central nervous system is characterized by precisely orchestrated, dynamic processes that commence at the embryonic stage and continue throughout postnatal life. Maintaining the balance between excitation/inhibition (E/I) in cortical neuronal circuits is crucial for normal brain function. General anesthetics (GAs) powerfully modulate neuronal activity by enhancing inhibition and/or inhibiting excitability, resulting in temporary loss of consciousness. Therefore, these agents can also induce aberrant neuroplasticity contributing to neurological dysfunction and abnormal behavioural phenotypes, particularly in the developing brain. While this impaired plasticity poses a risk, it also creates an opportunity to treat diseases characterised by abnormal neuroplasticity as core pathologies, such as neuropsychiatric disorders (NPDs). Over recent decades, intense investigations have revealed the neuroprotective and psychotherapeutic potential of GAs in treating neurological injuries and NPDs. Although promising, significant challenges remain, including optimizing dosages, administration duration, and intervals for non-anesthetic uses while minimizing adverse effects. Additionally, the molecular mechanisms underlying the dual roles of GAs - as neurotoxic agents and neurotherapeutic tools - require further elucidation. This review explores developmental neuroplasticity during critical periods, the mechanisms of GAs' action on neural circuits, and the current understanding of their neurotoxic and neuroprotective effects based on alterations in neuroplasticity. Furthermore, we highlight the therapeutic potential of GAs for neurological disorders with impaired neuroplasticity as the core pathological mechanism and propose directions for future research to unlock their full clinical utility.


  • Triiodothyronine attenuates neurocognitive dysfunction induced by sevoflurane in the developing brain of neonatal rats

    by Haicheng Huang, Pei Liu, Daqing Ma, Haixing Zhang, Huiling Xu, Jun Zhou, Hailin Zhao, Tianyun Zhao, Chuanxiang Li


  • Open Access

    Prenatal sevoflurane exposure causes abnormal development of the entorhinal cortex in rat offspring

    by Ying Gao, Tianyun Zhao, Yanxin Chen, Zhixiang Sun, Junming Lu, Ziwen Shi, Xingrong Song

    As a gamma-aminobutyric acid type A receptor agonist sevoflurane is a common general anesthetic used in anesthesia and affects the neural development in offspring. We hypothesized that sevoflurane could regulate interneurons via the neuregulin-1-epidermal growth factor receptor-4 (NRG1–ErbB4) pathway in the entorhinal cortex (ECT) of the middle pregnancy. Six female rats in middle pregnancy (14.5 days of pregnancy) were randomly and equally divided into sevoflurane (SeV) and control groups. The rats in the SeV group were exposed to 4% sevoflurane for 3 hours. The expression levels of NRG1 and ErbB4, parvalbumin (PV) and glutamic acid decarboxylase (GAD67), and N-methyl-D-aspartate receptor subunit 2A (NR2A) and subunit 2B (NR2B) in offspring were examined through immunohistochemistry. The pyramidal neurons in the ECT were examined via Golgi staining. The levels of NRG1 and ErbB4 were significantly decreased (P < 0.01) and the levels of PV and GAD67 (interneurons) were found to be decreased in the SeV group (P < 0.01). The level of NR2B was found to be increased while the level of NR2A being decreased in the SeV group (P < 0.01). The development of pyramidal neurons was abnormal in the SeV group (P < 0.05). Conclusively, prenatal sevoflurane exposure could lead to the disturbance of the interneurons by activating the NRG1–ErbB4 pathway and subsequently result in abnormal development of pyramidal neurons in middle pregnancy. Prenatal sevoflurane exposure in middle pregnancy could be potentially harmful to the neural development of rat offspring. This study may reveal a novel pathway in the influence mechanism of sevoflurane on rat offspring.


  • Open Access

    Prenatal sevoflurane exposure causes neuronal excitatory/inhibitory imbalance in the prefrontal cortex and neurofunctional abnormality in rats

    by Tianyun Zhao, Yanxin Chen, Zhixiang Sun, Ziwen Shi, Jingwen Qin, Junming Lu, Chuanxiang Li, Daqing Ma, Libing Zhou, Xingrong Song